Litigation Details for AstraZeneca LP v. Prinston Pharmaceutical Inc. (D. Del. 2015)

AstraZeneca LP v. Prinston Pharmaceutical Inc. (D. Del. 2015)

Docket		Date Filed	2015-11-16
Court	District Court, D. Delaware	Date Terminated	2019-01-02
Cause	35:1 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	Defendant	Referred To
Patents	6,251,910; 6,525,060; 7,250,419; 7,265,124; 8,425,934
Link to Docket	External link to docket

Details for AstraZeneca LP v. Prinston Pharmaceutical Inc. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-11-16				External link to document
2015-11-15	1		AstraZeneca’s U.S. Patent Nos. 6,251,910 (“the ’910 patent”), 6,525,060 (“the ’060 patent”), 7,250,419 (“… This is an action for patent infringement arising under the patent laws of the United States, … 2 of 12 PageID #: 2 ’124 patent”), and 8,425,934 (“the ’934 patent”) that are listed in the Approved… PATENTS-IN-SUIT 23. On June 26, 2001, the U.S. Patent and Trademark Office… 6 patent are valid and enforceable. AstraZeneca UK Limited is the owner of the ’910 patent by assignment	External link to document
2015-11-15	24		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,251,910; 6,525,060; 7,250,419…2015 2 January 2019 1:15-cv-01057 830 Patent Defendant District Court, D. Delaware	External link to document
2015-11-15	3		Date of Expiration of Patent: 6,251,910 (July 15, 2018) … Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …Received Notice: 10/03/2015. Date of Expiration of Patent: SEE ANDA.Thirty Month Stay Deadline: 1/20/2019… ) SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN ABBREVIATED NEW DRUG…2015 2 January 2019 1:15-cv-01057 830 Patent Defendant District Court, D. Delaware	External link to document

Litigation Summary and Analysis: AstraZeneca LP v. Prinston Pharmaceutical Inc. | 1:15-cv-01057

Last updated: March 10, 2026

Case Overview

AstraZeneca LP filed suit against Prinston Pharmaceutical Inc. in the District of Delaware (Case No. 1:15-cv-01057) alleging patent infringement related to formulations of pharmaceutical compounds used in approved drug products.

Patent and Alleged Infringement

• Patent in Question: U.S. Patent No. 8,278,349 (issued July 3, 2012), titled "Stable Pharmaceutical Compositions."
• Claims: Focuses on specific formulations for sustained-release pharmaceutical compositions involving a combination of active ingredients and excipients designed to improve stability and bioavailability.
• Accused Products: Prinston’s generic drug candidates that incorporate similar formulation techniques, raising allegations of patent infringement.

Procedural Timeline

• Filing date: October 29, 2015
• Initial filings: AstraZeneca filed a complaint asserting patent infringement.
• Response and motions: Prinston denied infringement and filed a motion to dismiss based on prior art and claim indefiniteness.
• Key rulings: The court dismissed certain claims in 2017 but allowed infringement allegations related to other claims to proceed.
• Trial date: Scheduled for March 2020 but postponed due to COVID-19.
• Current status: Disputed issues remain unresolved; case ongoing with discovery and motions pending.

Legal Issues

• Claim Construction: Disputed interpretation of terms such as "stable," "sustained-release," and "comprising."
• Prior Art: Defense challenged the validity of the patent, citing prior art references dating back before the patent’s priority date.
• Infringement: AstraZeneca claims Prinston’s formulations meet all elements of asserted claims; Prinston argues differences in formulation parameters mean no infringement.

Patent Validity Challenges

Prinston’s defense centers on prior art references including:

• US Patent No. 5,824,536
• Scientific publications from 2005 and 2010 demonstrating similar formulation techniques
• Arguments asserting claim patentability in view of these references

AstraZeneca maintains the patent’s claims are novel and non-obvious, protected under Patent Act sections 102 and 103.

Current Status and Implications

• Posture: The case remains active with pending summary judgment motions on validity and infringement.
• Potential Outcomes: Possible ruling of infringement, invalidity, or settlement.
• Market Impact: A favorable judgment for AstraZeneca could block generic entry and sustain patent exclusivity, impacting pricing and market share.
• Legal significance: Demonstrates the importance of claim interpretation and prior art considerations in pharma patent litigations.

Key Legal Considerations

• Patent validity hinges on the novelty and non-obviousness of the formulation.
• Claim construction significantly influences infringement analysis.
• The case demonstrates common defenses in pharma patent disputes, notably prior art and claim scope.

Strategic Insights for Industry

• Patent drafting should address clear, defensible claim language.
• Litigation may involve complex prior art analysis; early prior art searches are critical.
• Licensing negotiations could influence settlement and patent enforcement strategies.

Key Takeaways

• AstraZeneca’s patent litigation involves formulation patents with ongoing disputes over validity and infringement.
• Prior art references are central to the defense strategy of Prinston.
• Claim interpretation remains a pivotal issue, impacting infringement determinations.
• The outcome will influence patent life and generic entry timelines for associated drug products.
• The case reflects broader trends in pharmaceutical patent enforcement.

FAQs

1. What are the main legal issues in AstraZeneca LP v. Prinston Pharmaceutical Inc.?

The case revolves around patent validity and infringement, primarily focusing on claim scope, prior art challenges, and claim construction.

2. How does prior art influence this case?

Prior art references aim to invalidate the patent by demonstrating that the claimed formulations or methods existed before the patent’s priority date or are obvious variants.

3. What is the significance of claim construction in this case?

Claim construction determines what the patent claims cover. A narrow interpretation may limit infringement, while a broad one can lead to stronger infringement claims.

4. What are potential outcomes of the case?

Possible outcomes include judgment of infringement, invalidity, settlement, or dismissal. The case’s resolution will impact patent protection for AstraZeneca.

5. How does this case compare to typical pharma patent litigations?

It reflects common issues such as claim scope, prior art challenges, and the importance of detailed patent drafting to withstand validity challenges.

---

References

[1] United States District Court for the District of Delaware. AstraZeneca LP v. Prinston Pharmaceutical Inc., No. 1:15-cv-01057 (2015).